Sousan Karimi, M.D.

2000-2002 Harbor UCLA Medical Center, Division of Nephrology and Hypertension Torrance, CA Nephrology Fellowship Program

1997-2000 University of California, Irvine-Department of Internal Medicine Irvine, CA
Internal Medicine Residency Training Program

George Washington University School of Medicine Washington, D.C.
Doctor of Medicine, May 1997

1987-1992 University of California, Los Angeles- Department of Biochemistry Los Angeles, CA Bachelor of Science in Biochemistry, June 1992

1985-1987 Van Nuys High School

American Board of Nephrology, 2002-2012

American Board of Internal Medicine, 2001-2011

California Medical License, 1994-2004

Controlled Substance Registration Certicate (DEA), 2000-2004

A 30-Week, multicenter, randomized, double-blind, parallel-group study of the combination of ABT-335 and Rosuvastatin compared to Rosuvastatin Monotherapy in Dyslipidemic subjects with Stage 3 Chronic Kidney Disease.

Study to evaluate the improved management of iPTH with paracalcitol- centered therapy vs. cinacalcet therapy with low-dose vitamin d in hemodialysis patients with secondary hyperparathyroidism.

A Phase 2a, prospective, randomized, double-blind, placebo-controlled multicenter study to evaluate the safety and efficacy of Atrasentan on reducing albuminuria in type 2 diabetic nephropathy subjects who are currently being treated with an renin-angiotensin system inhibitor.

Phase 2, randomized, double-blind, placebo-controlle, parallel group, fixed dose study of AMG 223 in subjects with chronic kidney disease on hemodialysis with hyperphosphatemia.

A Phase III, Randomized, active-controlled, open-label, multi-center study of the safety and efficacy of AF37702 injection for the maintenance treatment of anemia in hemodialysis patients previously treated with epoetin

Outcome trial evaluating the efficacy and safety of Norditropin® on adult patients on chronic haemodialysis

A Phase IV, Long-term, Observational Safety Study in End Stage Renal Disease Subjects treated with lanthanum Carbonate (Fosrenol ®)

A Two-Arm, Randomized, Open-Label, Multicenter Study of Safety and Efficacy of Monthly Injections of RO0503821 versus Epoetin Alfa in Peritoneal Dialysis patients who self inject or receive in-center Injections.

Prospective, Open Label, Randomized multicenter study to demonstrate the efficacy and safety of intravenous (IV) RO0503821 for hemoglobin control in patients transitioning from chronic kidney disease. Stage 4 through dialysis.

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of AST-120 for Prevention of Chronic kidney Disease Progression in Patients with Moderate to Severe Chronic Kidney Disease.

A Randomized, Open-Label, multicenter study Epoetin Alfa comparing two extended-dosing regimens, Once-every-Two-Weeks, and Once- Every-Four-Weeks, with the Once-Weekly dosing regimen for maintenance treatment in anemic subjects with chronic kidney disease

An Open Label Randomized, Paralled-Group, Clinical Endpoint Bioequivalence Study of Generic Iron Sucrose Injection USP Versus Venofer® Iron Sucrose Injection USP in Hemodialysis Patients with Iron Deficiency

A randomized, double blind, placebo controlled, parallel group study to assess the effect of the endothelin receptor antagonist avosentan on time to doubling of serum creatinine, end stage renal disease or death in patients with type 2diabetes mellitus and diabetic nephropathy.

Evaluation Of Cinacalcet HCI Therapy to Lower cardio Vascular Events.

A Phase III Study if the Safety and Efficacy of Ferumoxytol (compared with oral iron) as an Iron Replacement Therapy in Chronic Kidney Disease Patients not on Dialysis.

An Open-Label, Single-Arm Study to Assess the Safety of Darbepoetin Alfa Manufactured by a Serum Free Bioreactor Technology in Subjects with Chronic Kidney Disease.

Phase IIIb, Multi-Center, Two-Cohort, Randomized Study, with an Open-Label Run-In and a Long-Term Extension Phase, Assessing an Extended Dose Range of Lanthanum Carbonate in End Stage Renal Disease Subjects Receiving Hemodialysis.

Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate Efficacy of Staph VAX, a Bivalent Staphylococcus aureus Glycoconjugate Vaccine in Adults on Hemodialysis.

Phase 3 Cinacalcet open label to reach K/DOQI levels

Phase 3 trial in treatment Strategies to Achieve Recommended K/DOQI Goals in ESRD Patients on Cinacalce.

Phase 4 Prospective, Randomized, double-blind, double-dummy, forced- titration, multicenter, parallel group, one year treatment trial to compare MICARDIS (telmisartan) 80 mg versus COZAAR (losartan) 100mg, in hypertensive type 2 diabetic patients with overt nephropathy (AMADEO Study)

Phase 3 Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of an Oral Calcimimetic Agent When Two Different Vitamin D Regimens are used in Subjects with Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD).

Phase 4 to evaluate subject preference for Aranesp administered administered once monthly, ie every 4 weeks (Q4W) or procrit administered once weekly (QW).